Normal view

Received — 10 January 2026 ⏭ Favourites

Nature Medicine
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial Renee R. Fedak · Rachel N. Ruggerie · Yufei Shan · Elizabeth J. Curvino · Juliana F. de Sousa · Shaji Daniel · Minhtran Ngo-Casi · Hafsa Kamboh · Tuan Vu · Hacer Durmuş · Tahseen Mozaffar · James F. Howard Jr. · Emily P. English · Albina Benson · Matthew T. Duvernay · Michael S. Singer · Murat V. Kalayoglu · Carsten Brunn · Aaron Bodansky · Mark S. Anderson · Joseph L. DeRisi · Samantha T. Garcia · David J. L. Yu · Kelsey C. Zorn · Metin Kurtoglu · Miloš D. Miljković · C. Andrew Stewart · Christopher M. Jewell · Charito Buensuceso · Lisa H. Tostanoski · Yi Zhang · Heng Xu · Chad A. Pope · Dina Schneider · Adam English · Atanas Filev · Jennifer Biaksangi · George Small · Michael Rivner · Michael A. Badruddoja · Bennett Myers · Sheetal Shroff · Adam Slanksy · Kelly Holley · Gregory Sahagian · Tara Quesnell · Marc H. Feinberg · Gabrielle DeMaria · Mithila Vullaganti · Carolina Barnett-Tapia · Meg Mendoza · Mona Irannejad · Zaeem Siddiqi · Ali A. Habib · Thomas Ragole · Mamatha Pasnoor · Rebecca E. Traub · Manisha Chopra · Natalie S. Grover · Yara A. Park · Matthew Ka
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-zAnalysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.
9 January 2026 at 08:00

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

By: Renee R. Fedak · Rachel N. Ruggerie · Yufei Shan · Elizabeth J. Curvino · Juliana F. de Sousa · Shaji Daniel · Minhtran Ngo-Casi · Hafsa Kamboh · Tuan Vu · Hacer Durmuş · Tahseen Mozaffar · James F. Howard Jr. · Emily P. English · Albina Benson · Matthew T. Duvernay · Michael S. Singer · Murat V. Kalayoglu · Carsten Brunn · Aaron Bodansky · Mark S. Anderson · Joseph L. DeRisi · Samantha T. Garcia · David J. L. Yu · Kelsey C. Zorn · Metin Kurtoglu · Miloš D. Miljković · C. Andrew Stewart · Christopher M. Jewell · Charito Buensuceso · Lisa H. Tostanoski · Yi Zhang · Heng Xu · Chad A. Pope · Dina Schneider · Adam English · Atanas Filev · Jennifer Biaksangi · George Small · Michael Rivner · Michael A. Badruddoja · Bennett Myers · Sheetal Shroff · Adam Slanksy · Kelly Holley · Gregory Sahagian · Tara Quesnell · Marc H. Feinberg · Gabrielle DeMaria · Mithila Vullaganti · Carolina Barnett-Tapia · Meg Mendoza · Mona Irannejad · Zaeem Siddiqi · Ali A. Habib · Thomas Ragole · Mamatha Pasnoor · Rebecca E. Traub · Manisha Chopra · Natalie S. Grover · Yara A. Park · Matthew Ka

9 January 2026 at 08:00

Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z

Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.